1. Home
  2. QSI vs MLYS Comparison

QSI vs MLYS Comparison

Compare QSI & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Quantum-Si Incorporated

QSI

Quantum-Si Incorporated

HOLD

Current Price

$0.77

Market Cap

165.6M

Sector

Health Care

ML Signal

HOLD

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$27.93

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QSI
MLYS
Founded
2013
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
165.6M
2.5B
IPO Year
2020
2023

Fundamental Metrics

Financial Performance
Metric
QSI
MLYS
Price
$0.77
$27.93
Analyst Decision
Buy
Strong Buy
Analyst Count
2
7
Target Price
$1.00
$48.67
AVG Volume (30 Days)
2.1M
1.1M
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
28.17
37.43
EPS
N/A
N/A
Revenue
$2,436,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$618.07
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.69
$22.30
52 Week High
$3.10
$47.65

Technical Indicators

Market Signals
Indicator
QSI
MLYS
Relative Strength Index (RSI) 49.69 50.33
Support Level $0.70 $25.56
Resistance Level $0.79 $28.14
Average True Range (ATR) 0.03 1.68
MACD 0.00 -0.06
Stochastic Oscillator 57.55 39.69

Price Performance

Historical Comparison
QSI
MLYS

About QSI Quantum-Si Incorporated

Quantum-Si Inc is a life sciences company focused on proteomics research and analytical technologies. It develops single-molecule detection platforms designed to enable next-generation protein sequencing (NGPS) and large-scale protein analysis. Its technology supports massively parallel sequencing of proteins and can also be applied to the study of nucleic acids, providing tools for researchers and clinical applications in molecular analysis. The company's revenue is derived from sales of products and services.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Share on Social Networks: